These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26823385)

  • 1. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
    Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
    Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.
    Yau TK; Sze H; Soong IS; Hioe F; Khoo US; Lee AW
    Hong Kong Med J; 2008 Apr; 14(2):130-5. PubMed ID: 18382020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
    Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
    Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
    Francz M; Egervari K; Kardos L; Toth J; Nemes Z; Szanto J; Szollosi Z
    J Clin Pathol; 2010 Apr; 63(4):341-6. PubMed ID: 19965795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
    Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
    J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 overexpression of breast cancers in Hong Kong shows good concordance with HER2 amplification by fluorescence in-situ hybridisation study.
    Chan JK; Tsang WY; Lo ES; Wong MC
    Hong Kong Med J; 2008 Aug; 14(4):333; author reply 334. PubMed ID: 18685172
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
    Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer:  A Cohort Study Emphasizing Equivocal Cases.
    Shao T; Wood M; Wing A; Hnatovska M; Mendes M; Brendan Mullen J; Chang MC
    Am J Clin Pathol; 2016 Sep; 146(3):339-45. PubMed ID: 27543979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
    van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
    Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.